Pulse ·

TGA issues class-wide eye-safety warning for GLP-1 weight-loss drugs

By Dr HB Lo, FACRRM 4 min read
Verdict Yes — worth knowing about

The TGA has issued a class-wide safety warning for all GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda), and dulaglutide (Trulicity) — linking them to non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can cause permanent vision loss.

Thirty-six cases have been reported in Australia. The absolute risk is low — an estimated 2 to 18 additional NAION cases per 100,000 users annually — but the outcome can be irreversible. If you are on any of these medications and notice sudden vision changes in one eye, seek urgent ophthalmological assessment.

What just happened

The Therapeutic Goods Administration issued a class-wide safety update this week for all GLP-1 receptor agonists — the medication class that includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda), and dulaglutide (Trulicity). The update concerns a rare but serious eye condition called non-arteritic anterior ischaemic optic neuropathy, abbreviated as NAION.

NAION is a sudden, painless loss of vision in one eye caused by an interruption to the optic nerve’s blood supply. The TGA updated the product information for the entire GLP-1 drug class, adding warnings for health professionals and patients, following 36 documented Australian adverse event cases. The absolute risk is estimated at 2 to 18 additional NAION cases per 100,000 users annually — but the outcome can be permanent.

The timing matters: the TGA first flagged this potential link after a July 2024 JAMA Ophthalmology study, and European regulators and the WHO issued similar alerts in 2025. Australia’s update brings our product information into line with international regulators. This is pharmacovigilance working as it should — a research signal confirmed in real-world adverse event data, then translated into updated clinical guidance.

The both-and

The risk is real — and needs context

Thirty-six Australian cases. An estimated 2 to 18 additional NAION events per 100,000 users annually. These numbers are not trivial when millions of Australians are now on GLP-1 receptor agonists — a class that has transformed how type 2 diabetes and obesity are managed in general practice.

At the same time, the established evidence base for these medications includes cardiovascular protection, glycaemic control, and clinically meaningful weight loss. None of that has changed. The TGA has not recommended stopping treatment. What the warning does is add NAION to the existing safety profile — alongside the already-documented risks of pancreatitis, thyroid C-cell effects, and gastrointestinal adverse events — so that prescribers and patients can make informed decisions.

Who is at higher risk?

The TGA named specific pre-existing factors that raise baseline NAION risk: diabetes itself, high blood pressure, sleep apnoea, and a particular optic disc anatomy (small cup-to-disc ratio, sometimes called “disc at risk”). These conditions overlap substantially with the patient population most likely to be prescribed GLP-1 receptor agonists. People with type 2 diabetes and hypertension are exactly the group on semaglutide or tirzepatide — meaning the risk factors and the indicated population are not cleanly separable.

That does not make the signal dismissible. It means GPs prescribing these medications have most of the information already in hand to assess individual risk, and the updated product information gives them a clear framework for counselling.

What this does not mean

The absolute risk, framed differently: 99,982 to 99,998 people per 100,000 GLP-1 users annually will not develop NAION. The large majority of people on these medications — even those with named risk factors — will not experience this complication. The warning does not override the benefits for the patients for whom these medications are indicated.

What the warning does mean is that sudden vision changes in a patient on a GLP-1 medication should not be attributed to other causes without proper ophthalmological evaluation. The “painless” aspect of NAION is precisely what creates diagnostic delay: if it doesn’t hurt, the patient waits. That wait can determine the extent of permanent damage.

The specific action the TGA is asking for is clear: patients should seek immediate ophthalmological assessment if they experience any sudden change in vision. GPs should refer urgently if NAION is suspected. That is a concrete, executable piece of guidance — not a reason to stop treatment, but a reason to know the drill before you need it.

My two cents

GLP-1 receptor agonists are among the most consequential medications in general practice right now. The evidence for their metabolic and cardiovascular benefits has genuinely transformed how obesity and type 2 diabetes are treated, and the demand from patients — many of them women in their 40s and 50s managing weight, blood sugar, and heart risk simultaneously — has been substantial and is not going away.

This update does not change that picture. What it changes is what a thorough medication review conversation looks like. If you are on Ozempic, Wegovy, Mounjaro, Saxenda, or Trulicity, there are two questions worth raising with your GP: Are any of my existing health conditions on the TGA’s NAION risk factor list? And if my vision changes suddenly, what do we do?

The answer to the second question is: seek urgent ophthalmological assessment, not wait and see.

Sudden, painless vision change in one eye is an ophthalmological emergency regardless of cause. The TGA has now put this explicitly in the product information for GLP-1 medications. The update asks for awareness and a prompt action plan — nothing more, and nothing less.

Verdict: yes — class-wide TGA safety update for medications taken by a significant proportion of this readership.

Sources cited

  1. TGA issues GLP-1 RA class-wide safety update. RACGP newsGP, 23 July 2026. https://www1.racgp.org.au/newsgp/clinical/tga-issues-glp-1-ra-class-wide-safety-update
  2. TGA news and safety resources. https://www.tga.gov.au/news-and-resources/news

Frequently asked questions

  • Should I stop Ozempic or Wegovy because of the eye risk?

    The TGA has not recommended stopping GLP-1 medications. The absolute risk is low — 2 to 18 additional NAION cases per 100,000 users per year — and the established benefits for weight management, blood sugar control, and cardiovascular protection remain unchanged. Any decision about continuing or adjusting treatment is one to make in consultation with the GP who prescribed them, weighing individual risk factors.

  • What is NAION and what symptoms should I watch for?

    Non-arteritic anterior ischaemic optic neuropathy (NAION) is a sudden, painless loss of vision in one eye caused by an interruption to the optic nerve's blood supply. It is distinct from gradual diabetic eye changes. The TGA advises seeking immediate ophthalmological assessment for any sudden vision change while on a GLP-1 medication — do not wait to see whether it resolves on its own.

  • Am I at higher risk if I have diabetes or high blood pressure?

    Yes. The TGA has named diabetes, high blood pressure, sleep apnoea, and a specific optic disc anatomy (small cup-to-disc ratio, sometimes called 'disc at risk') as pre-existing factors that raise baseline NAION risk. These conditions overlap substantially with the population most likely to be prescribed GLP-1 medications. If you have any of them, discussing eye monitoring with your GP is reasonable.